Bankrupt Biotech Targets Nixon Peabody, Mintz Levin

, The Litigation Daily

   | 0 Comments

Neogenix Oncology Inc., a bankrupt would-be developer of cancer diagnostic and treatment products, blamed its outside lawyers for allowing the company to pursue an illegal fund-raising strategy for more than five years.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202664351398

Thank you!

This article's comments will be reviewed.